<DOC>
	<DOCNO>NCT00932113</DOCNO>
	<brief_summary>The objective study compare mechanism action adalimumab methotrexate subject psoriasis .</brief_summary>
	<brief_title>Mechanism Action Study Psoriasis</brief_title>
	<detailed_description>Both methotrexate adalimumab FDA-approved drug treatment moderate severe psoriasis . The two treatment , methotrexate adalimumab , show efficacy psoriasis , however profile differ . In CHAMPION Study , adalimumab-treated , moderate severe psoriasis patient achieve PASI 75 16 week compare treated methotrexate ( 80 % vs. 36 % ) . The reason difference poorly understood . No direct comparative mechanism action study psoriasis patient methotrexate adalimumab ( tumor necrosis factor blocker ) report . With etanercept , another tumor necrosis factor blocker , vivo mechanism study scientific rigor . These study demonstrate etanercept regulates multiple pro-inflammatory pathway ( show Table 1 protocol ) . To date , similar study adalimumab methotrexate . In order understand molecular cellular basis differential clinical efficacy adalimumab methotrexate , essential compare mechanisms action psoriatic plaque . Biopsies perform , study biomarkers proposal immunohistochemistry , real-time polymerase chain reaction , gene array .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adults 1885 year age moderate severe psoriasis , general good health determine PI base upon result medical history , laboratory profile , physical examination , candidate systemic phototherapy Presence psoriatic plaque &gt; 2cm area biopsied repeatedly . Men must agree avoid impregnate woman study . Women eligible participate study meet one follow criterion : Women postmenopausal ( &gt; 1 year ) , sterile , hysterectomized Women childbearing potential must undergo monthly pregnancy test study agree use two follow method contraception throughout 60 day last dose study drug : Oral contraceptive Transdermal contraceptive Injectable implantable method Intrauterine device Barrier method ( diaphragm condom spermicide ) Abstinence Tubal Ligation also consider form Birth control Patients &lt; 18 &gt; 85 year old Absence psoriatic plaque &gt; 2cm diameter Active guttate , erythrodermic , pustular psoriasis time screen visit Evidence skin condition screen ( e.g . eczema ) would interfere evaluation effect study medication Inability understand consent process Receipt investigational drug , psoralen+ultraviolet A oral systemic treatment within 4 week study drug initiation Biologics within 3 month study initiation Topical steroid , topical vitamin A D analog preparation , Ultraviolet B therapy anthralin within 2 week study drug initiation . ( Exceptionstable regimen class III topical steroid scalp , axilla , groin ) Methotrexate within 6 week study initiation History treatment adalimumab History primary nonresponse methotrexate , infliximab etanercept History discontinuation methotrexate tumor necrosis factor ( TNF ) blocker safetyrelated reason make unwise restart either type drug Any internal malignancy within 5 year ( exclude fully excise cutaneous basal cell squamous cell carcinoma ) Pregnancy , practice effective birth control , inability practice safe sex length study Lactation Subjects know hypersensitivity adalimumab methotrexate component know antibody etanercept History alcohol drug abuse one year study Known HIVpositive status immunesuppressing disease Presence grade 3 4 infection &lt; 30 day prior screen visit , screen visit first day treatment study , time study opinion PI would preclude participation study Any grade 3 4 adverse event , laboratory toxicity , time screen visit time study , opinion PI would , preclude participation study Serum creatinine &gt; 3.0 mg/dL ( 265 micromoles/L ) Serum potassium &lt; 3.5 mmol/L &gt; 5.5 mmol/L Serum alanine aminotransferase aspartate aminotransferase &gt; 3 time upper limit normal lab Platelet count &lt; 100,000/mm3 White blood cell count &lt; 3,000/mm3 Hgb , Hct , red blood cell outside 30 % upper low limit normal Lab Receipt live vaccine 1 month prior study History tuberculosis , and/or positive PPD skin test/chest xray screen without appropriate treatmenttreatment latent tuberculosis ( positive PPD test ) must initiate prior therapy adalimumab methotrexate Chronic hepatitis B C infection , history multiple sclerosis , transverse myelitis , optic neuritis epilepsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>tumor necrosis factor ( TNF ) inhibitor</keyword>
	<keyword>tumor necrosis factor ( TNF ) blockade</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>treatment</keyword>
	<keyword>mechanism</keyword>
	<keyword>psoriasis</keyword>
</DOC>